Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuroblastoma breakpoint family member 20 (NBPF20) is a protein-coding gene located on human chromosome 1q21.1 and part of the NBPF gene family, which is notable for primate-lineage-specific expansions and high copy number variation[1][3][6]. NBPF genes are characterized by multiple tandem DUF1220 protein domains, and copy number variations in this region are linked to various neurodevelopmental disorders and certain cancers, including neuroblastoma[3][4][6]. While altered expression and copy number have pathogenic significance, especially in neurological development and tumorigenesis, the precise molecular functions of NBPF20 remain poorly understood and it is not classified as a canonical therapeutic target such as receptor, enzyme, or transcription factor[3][6][7].\n\nNote: There is no evidence NBPF20 is a direct drug target, established biomarker, or safety concern. Its primary relevance is as a member of a gene family undergoing recent evolutionary expansion, implicated in copy number variation disorders and, indirectly, in cancer and developmental diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuroblastoma breakpoint family member 20 (NBPF20).